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Abstract
Purpose: The purpose of this study was to validate a newly developed diffuse optical
tomography (DOT) system on benign cysts in the breast.
Procedures: Eight patients with 20 benign cysts were included. Study procedures consisted of
optical breast imaging and breast magnetic resonance imaging (MRI) for comparison. A
reconstruction algorithm computed three-dimensional images for each of the four near-infrared
wavelengths used by our DOT system (Philips Healthcare, Best, The Netherlands). These images
were combined using a spectroscopic model to assess tissue composition and lesion size.
Results: Twenty cysts were analyzed in eight patients. By using the spectroscopic information,
13 of 20 cysts (65%) were visualized with DOT, confirming their high water and low total
hemoglobin content. Lesion size and location showed good agreement with MRI; Pearson
correlation coefficient was 0.7 (p G 0.01).
Conclusions: DOT can visualize benign cysts in the breast and elucidate their high water and
low total hemoglobin content by spectroscopic analysis.
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Introduction
D
iffuse optical tomography (DOT) is a novel imaging
technique that uses near-infrared (NIR) light in the
wavelength range of ∼700 to 1,000 nm to assess optical
properties of tissue [1]. Light absorption at these wave-
lengths is minimal, allowing for sufficient tissue penetration
(up to 15 cm) in breast imaging. Information on tissue
composition, i.e., concentrations of oxy- and deoxyhemo-
globin, water, and lipid, can be obtained by combining
images acquired at various wavelengths (spectroscopic
imaging). In a malignant tumor, hemoglobin (Hb) concen-
tration is directly related to angiogenesis, a key factor
required for tumor growth and metastases [2]. In addition,
the proportions of oxy- and deoxyhemoglobin change in
such a tumor due to its metabolism [3]. By measuring
concentrations of the main chromophores in the breast,
discrimination of benign and malignant tumors may be
possible with DOT. This technique could complement
currently used breast imaging modalities, ultrasound, X-ray
mammography, and magnetic resonance imaging (MRI) in
the diagnosis and early detection of breast cancer. Ultra-
sound can easily distinguish cysts from solid lesions but is
less specific than X-ray mammography in differentiating
benign from malignant masses [4]. It is used as an adjunct to
X-ray mammography, not as stand-alone screening tool, and
is limited by its operator dependence as well as the lack of
standardized examination criteria [5]. The overall sensitivity
of X-ray mammography for breast cancer detection is
moderate (75%), though in (young) women with dense
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women are at a four to six times increased breast cancer risk,
this is a major disadvantage of X-ray mammography [7].
Magnetic resonance imaging has high sensitivity (990%),
also in dense breasts, but is very costly [8, 9]. Positive
predictive value of MRI is decreased in lesions G5m m[ 10].
As lesion size upon diagnosis decreases with more efficient
screening programs, the need for a non-invasive tool that
provides more specific information on lesions becomes
relevant. DOT has great potential in the early detection of
breast cancer if target-specific fluorescent probes allow for in
vivo imaging of molecular changes associated with cancer
formation [11]. Moreover, DOT uses no ionizing radiation
and can thus be used repeatedly, also in younger women.
The technique is relatively inexpensive leading to relatively
easy access which is an important advantage in regions
where no MRI scanner is available.
Optical imaging systems are still in their infancy, and
several research groups are investigating different techniques
[12]. Three distinct illumination methods are being employed:
time domain [13–15], frequency domain [16, 17], and
continuous wave [18–20]. Some groups combine their optical
system with another modality, such as ultrasound or MRI
[17, 21]. Furthermore, compression of the breast [13–15],
optical fluid [13], and various wavelengths in the NIR range
are being investigated. To create a robust platform for optical
breast imaging, it is important to validate systems in an
adequate manner. We started our validation process in a simple
breast model, benign cysts, with the aim to determine the
optical characteristics of these lesions. MRI was the benchmark
for DOT because it also provides three-dimensional data and
has excellent soft-tissue contrast.
The purpose of this study was to validate a newly
developed DOT system on benign cysts in the breast.
Methods
Patients
Eight women (mean age 48, range 38–60) diagnosed with a total of
20 cystic breast lesions were prospectively included between
October 2006 and September 2007 at the University Medical
Center Utrecht, the Netherlands. Patients were asked to participate
in the study if a benign cyst larger than 10 mm was found by
ultrasound and needle aspiration had not yet been performed, since
this would influence the optical images. Additional to the normal
clinical diagnostic procedure of mammography and ultrasound,
patientsunderwentopticalimaging andnoncontrast-enhanced MRI
as part of the study protocol. Patients with contra-indications for
MRI were excluded. The protocol was approved by the ethics
committee of the University Medical Center Utrecht, and written
informed consent was obtained from all patients.
Optical Imaging
Data AcquisitionDiffuse optical tomography scans were performed
on a Philips Diffuse Optical Tomography system (Philips Healthcare,
Best, the Netherlands). A patient was placed in the prone position on the
system bed with one breast suspended in the cup (Fig. 1). The scanning
module of the DOT system consists of a cup with a total of 507 optical
fibers mounted on the surface. The 253 source fibers on all sides of the
cup are connected to a fiber switch to direct the light of four
continuous-wave solid-state lasers into the cup. These fibers are
interleaved with 254 detector fibers connected to 254 detectors. For
each scan, the cup was filled with a matching fluid that has optical
properties approximately equal to those of the average breast. This
matching fluid enables a stable optical coupling between the fibers
and the breast, and it eliminates optical shortcuts of the diffuse
light around the breast. During imaging, the breast was sequen-
tially illuminated with continuous-wave near-infrared light from all
source positions. Light emanating from the breast was detected for
each source position by the detector fibers on all sides of the cup.
Images were obtained at four discrete wavelengths (690, 730, 780,
and 850 nm). Each breast is scanned separately. The duration of
the examination was approximately 1 min per wavelength, in total
about 10 min per patient.
Image ReconstructionAfter optical data acquisition, three-dimension-
al absorption images were reconstructed by a linear reconstruction
algorithm based on the Rytov approximation[22–24]. One image was
calculated for each wavelength. Since the reconstruction algorithm
assumes constant scattering throughout the measurement cup, there is
an influence of scattering variations on the reconstructed absorption
images. If the average scattering of the breast is different from the
scattering of the fluid, there will be an offset on the reconstructed
breast absorption. If there is a variation of the scattering within the
breast, the reconstructed image also shows features due to these
variations.
Spectral Post-processingIn addition, optical images of the four
wavelengths were combined to convert the absorption coefficients
into hemoglobin, oxyhemoglobin (HbO2), water, and lipid
Fig. 1. The Philips diffuse optical tomography system.
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phores present in the breast. To determine the concentrations, we
used the relation c ¼ " ½ 
 1 a,w h e r ec refers to the concentrations
of the four chromophores, [ɛ] is a 4×4 matrix of molar absorption
values of the four chromophores for the four wavelengths used by
the DOT machine, and μa is the vector of reconstructed absorption
coefficients at each wavelength. The spectra that were used to fill
[ɛ] are shown in Fig. 2 (data taken from [25–27] for water, lipid,
hemoglobin, and oxyhemoglobin, respectively). Finally, the Hb and
HbO2 concentrations were added to obtain a measure of the total
hemoglobin concentration. However, as a consequence of using
continuous-wave light, our reconstruction algorithm could not
account for scattering variations in the breast, in contrast with other
research groups using time domain or frequency domain techniques
[13–17]. In addition, since the breast contains more than the four
chromophores mentioned, this model only approximates the breast
composition. We therefore choose to discuss “enhancement” by
chromophores rather than their absolute concentration. Three-
dimensional enhanced-water maps, with high signal intensity for
high water concentration, and three-dimensional enhanced-blood
maps, with high signal intensity for high blood concentration (and
low signal intensity in case of blood depletion), were generated.
MRI
Non-contrast enhanced breast MRI was performed on a 3.0T
clinical MR system (3.0T Achieva, Philips Healthcare, Best, The
Netherlands). Patients were placed in prone position on a dedicated
four-element SENSitivity Encoding (SENSE)-compatible phased-
array bilateral breast coil (MRI devices, Würzburg, Germany)
utilized for simultaneous imaging of both breasts. The scan
protocol included an axial high-resolution T1-weighted fast
gradient echo fat-suppressed series (TE/TR 1.7/4.5 ms; inversion
delay SPAIR 130 ms; flip angle 10°; field of view (FOV) 340×
340 mm
2, acquired voxel size 0.66×0.66×1.6 mm
3, reconstructed
voxel size 0.66×0.66×0.80 mm
3) and an axial T2-weighted fat-
suppressed series (TE/TR 120/9,022 ms; inversion delay Spectral
Selection Attenuated Inversion Recovery (SPAIR) 125 ms; flip
angle 90°; FOV 340×340 mm
2, acquired voxel size 1.01×1.31×
2.0 mm
3, reconstructed voxel size 0.66×0.66×2.00 mm
3).
Image Interpretation and Statistics
MRI data was used to derive the location of the cysts. Size
measurements were performed on the axial MR slices showing the
largestdiametersofthecysts.Thisinformationwasusedasareference
standard for the optical measurements.
All four absorption images were viewed on the console of the
DOT system. The visibility of the lesions on DOT was assessed in
a qualitative manner. When the reconstructed values at the lesion
site (derived from MRI) were clearly lower or higher than those of
the surrounding tissue (background), the cyst was considered
visible. Lower values can be expected when absorption and/or
scattering properties of the lesion are lower than those of the
background. The physiological maps of water and total hemoglobin
were evaluated and compared to the MRI data.
Maximum diameters of the lesions were measured on the axial
view of the physiological maps from the full width at half
maximum of the signal intensity through the center of the cyst
region, and compared to the maximum diameters measured on the
axial MR images. The Bland Altman method was used to measure
the agreement of lesion size between the MRI and DOT measure-
ments [28]. The Pearson correlation coefficient was calculated to
estimate the correlation between the two methods.
Results
Eight women with 20 benign cysts underwent optical breast
i m a g i n gw i t ht h en e wD O Ts y s t e ma n db r e a s tM R If o r
comparison. All cysts were clearly visible on MRI,
s h o w i n gh i g hs i g n a li n t e n s i t yo nt h eT 2w e i g h t e di m a g e s .
Maximum lesion sizes measured on the MR images ranged
f r o m8t o4 0m m( m e d i a ns i z e2 1m m ) .C y s t ss m a l l e rt h a n
5 mm detected on MRI were not taken into account in this
study.
Based on the absorption images only, six of the 20
benign cysts (30%) were clearly distinguishable with DOT.
These lesions had lower absorption compared to the
surrounding tissue for all of the four wavelengths (Fig. 3).
By using the information from the physiological maps, 13
of 20 benign cysts (65%) were evident on DOT. The
enhanced-water and -blood maps showed high water
content and low total hemoglobin content at the position
of these cysts (Fig. 4).
Detected lesions had maximum diameters of 15 mm
and larger. Two cysts with diameters of 10 and 8 mm on
M R Iw e r en o tv i s i b l ew i t hD O T .F i v ec y s t st h a tw e r e
located close to the chest wall were not detected because
they were outside the field of view of the current DOT
system.
The maximum diameters of the detected lesions are
plotted in Fig. 5. There was a good agreement between the
optical measurements and MRI, with a Pearson correlation
coefficient of 0.7 (pG0.01). Figure 6 displays the Bland
Fig. 2. Absorption spectra of the main constituents of
breast tissue, represented in terms of absorption coefficients
for water and lipid, and molar absorption coefficients for
hemoglobin and oxyhemoglobin. Data were taken from [25–
27] for water, lipid, Hb, and HbO2, respectively. The wave-
lengths of the lasers used for the DOT measurements are
indicated by the vertical black arrows.
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and DOT are plotted against the mean of the two methods.
The three horizontal lines represent the mean difference
(middle line) and the limits of agreement (outer lines: mean
difference±2SD) [28]. DOT overestimated the lesion size on
average by 2.5 mm (mean difference MRI-DOT, −2.5 mm;
95% confidence interval, −6.4 to 1.3).
Discussion
In this study, we validated a new DOT system for breast
imaging on benign cysts with MRI as a benchmark. Cysts
were visible with DOT, and spectroscopic analysis showed
high water and low total hemoglobin content. Lesion sizes
on DOT correlated well with MRI measurements.
As described previously, most recent optical imaging studies
focused on solid tumors. They showed higher absorption for
carcinomas than for the surrounding normal parenchyma due to
increased hemoglobin content [13–19, 21]. Few studies
reported on the characterization of cysts with optical imaging
devices. Ntziachristos et al. reported on low absorption for
cysts [21], and Taroni et al. described low scattering in cysts
[15]. In Gu et al. [20], it was shown that cysts had a lower
optical attenuation than the background. They described both
low absorption and low scattering in four of the cysts and only
low scattering in one case.
In our study, the cysts visible on optical absorption
images appeared as regions darker than the surrounding
tissue (Fig. 3). This could be caused by either lower
absorption properties, lower scattering properties, or the
combination of both. The use of continuous-wave light
transmission hampers the distinction between scattering and
absorption [29]. With other illumination techniques, time
domain (e.g., used by the groups of Intes, Rinneberg, and
Taroni [13–15]) and frequency domain (e.g., used by the
groups of Tromberg and Zhu [16, 17]), it is more
straightforward to make this distinction. These methods have
the disadvantage of being more expensive and requiring
longer acquisition times than the continuous-wave technique.
In one of the patients in our study, an opposite effect was
seen: the cyst had a higher signal intensity (higher absorption/
scattering) compared to the surrounding tissue, with lower
water and higher total hemoglobin content on the physiolog-
ical maps. On MRI and ultrasound, this cyst had similar
characteristics as the other cysts in our study. Such an
opposite effect was also reported by Gu et al. who described
a cyst with both higher absorption and higher scattering
compared to the surrounding tissue [20]. As suggested by Gu
et al., an explanation for this opposite effect could be a
different content of the cyst. To verify this hypothesis, future
aspiration and evaluation of cyst contents could be considered.
Spectroscopic analysis of the cysts in our study elucidated
their high water content and low hemoglobin content
(Fig. 4). Combining the four wavelengths improved lesion
detection: without spectral information only six cysts were
visible, while with spectroscopic analysis 13 of the 20
lesions could be detected.
Seven of the 20 cysts were not detected by our DOT
system. We believe there are two reasons for this. First, five
cysts were located too close to the chest wall for the current
dimensions of the optical scanner to image. These lesions
Fig. 3. Example of the optical absorption images of one patient for the four wavelengths (690, 730, 780, and 850 nm). The cyst
(40 mm in diameter) shows low signal intensity (low absorption) in all of the four wavelengths.
S. van de Ven, et al.: Diffuse Optical Tomography of the Breast 67Fig. 4. Examples of images of three patients (a, b, c): T2 weighted MRI with fat suppression compared to the enhanced-water
maps and the enhanced-blood maps of the optical data sets. The cysts show a high signal intensity on the MRI and the
enhanced-water maps (high water content) and a low signal intensity on the enhanced-blood maps (low blood content).
Asterisk nipple.
Fig. 5. Scatter plot of diameters in millimeters measured
with MRI (x-axis) and DOT (y-axis). Pearson correlation
coefficient, 0.7 (pG0.01). If merged lesions (double asterisk)
were excluded from analysis, Pearson correlation coefficient
increased to 0.8 (pG0.01).
Fig. 6. Bland Altman plot of lesion sizes in millimeters.
Absolute differences between MRI and DOT (y-axis) are
plotted against the mean of the two methods (x-axis). The
horizontal lines represent the mean difference (middle line)
and limits of agreement (mean difference±2SD). Double
asterisk merged lesions.
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optical fibers in the cup to influence the light pathways.
Advances in cup geometry are feasible and would result in
improved visualization of lesions near the chest wall.
Second, spatial resolution of DOT is poor [1, 30], resulting
in a lower signal-to-noise ratio and limited detectability for
small lesions: two lesions of 10 and 8 mm were too small to
be visualized by our DOT system. One of these cysts was
probably merged with the nearby larger lesion in the optical
image, leading to a significant overestimation of that cyst
(Fig. 5). All detected lesions had diameters of at least 15 mm.
For lesions visible on DOT images, a good agreement in
lesion size with MRI was found (Figs. 5 and 6). Pearson
correlation coefficient was 0.7 (pG0.01). If the lesion that we
believed to be merged with the nearby lesion was excluded
from the analysis, Pearson correlation coefficient increased to
0.8 (pG0.01). On average, lesion size was overestimated by
2.5 mm with DOT, and most optical size measurements did
not differ more than 6 mm from MRI measurements. By
exclusion of the supposedly merged lesion, overestimation
was reduced to 1.3 mm (mean difference MRI–DOT,
−1.3 mm; 95% confidence interval, −4.4 to 1.7). Lesions
overestimated by more than 6 mm with DOT were located in
a central position in the cup where the spatial resolution of the
system is the lowest, leading to partial volume effects.
Lesion detection is more difficult and size measurement
less precise in the center of the cup compared to the edge of
the cup because longer light pathways decrease spatial
resolution. This may be a limitation in large breasts with
centrally located lesions. Optical data acquisition using slab
geometry with slight breast compression could offer a
solution to this problem. We did not encounter variations in
lesion visibility for different breast densities in this data set.
Typically, close to the boundary of the cup, structures
were noted with very high signal intensities (e.g., Fig. 4,
patient c). These are reconstruction artifacts caused by
inconsistencies in the data. They show up strongest at the
source and detector positions and can be identified as
artifacts due to their position at the cup wall. Also, in most
patients, the nipples were visible as regions of high signal
intensity on the enhanced-blood maps (Fig. 4, patient b) and
low signal intensity on the enhanced-water maps.
For evaluation of the optical data, we used the knowledge
of lesion location from the MRI data. This approach in
image interpretation possibly resulted in the exclusion of
false-positive findings, such as the high signal intensities
caused by artifacts. Blinded reading of images should be
performed to give a better estimate of the diagnostic value.
This study was the first step in the validation of a new
DOT system. Further steps will involve validation on
malignant breast lesions (including discrimination of malig-
nant from benign lesions, such as cysts) and feasibility
studies with fluorescent optical probes to increase specific-
ity. Such fluorescent probes emit photons at predefined
wavelengths after excitation by laser light and have already
been used successfully in animal experiments [31, 32].
In conclusion, we initiated the validation of a new DOT
system on benign cysts in the breast. DOT was able to
visualize cysts and elucidate their high water and low total
hemoglobin content by spectroscopic analysis.
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